Wolverine Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.77M Sell
22,340
-475
-2% -$35.7K 0.02% 636
2026
Q1
$1.71M Sell
22,815
-7,700
-25% -$608K 0.02% 613
2025
Q4
$2.41M Buy
+30,515
New +$2.3M 0.02% 545
2021
Q3
Sell
-783
Closed -$29.5K 2162
2021
Q2
$31K Buy
+783
New +$30.7K ﹤0.01% 1796
2020
Q3
Sell
-32
Closed -$1.78K 1653
2020
Q2
$1K Buy
+32
New +$1.78K ﹤0.01% 1493
2017
Q1
Sell
-187,742
Closed -$8.43M 1277
2016
Q4
$8.98M Buy
+187,742
New +$7.43M 0.12% 158

Other funds holding IONS

Wolverine Asset Management's IONS Position: Q2 2026 in Review

Wolverine Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 2.1% in Q2 2026, selling an estimated $35.7K and leaving 22,340 shares worth $1.77M. The position accounts for 0.02% of the portfolio, ranked #636.

Wolverine Asset Management first reported a position in IONS in Q4 2016 and has held it in 6 quarters since. The position peaked at $8.98M in Q4 2016. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Wolverine Asset Management held 22,340 shares of Ionis Pharmaceuticals worth $1.77M as of Q2 2026.
  • Wolverine Asset Management sold 475 Ionis Pharmaceuticals shares in Q2 2026, an estimated $35.7K.
  • Ionis Pharmaceuticals made up 0.02% of Wolverine Asset Management's portfolio in Q2 2026, its #636 holding.
  • Wolverine Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2016 and has held it in 6 quarters since.
  • Wolverine Asset Management's Ionis Pharmaceuticals position peaked at $8.98M in Q4 2016.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Wolverine Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.